Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of LY3209590 formulations in healthy participants
NCT05914688Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised trial of Insulin efsitora alfa in diabetes mellitus (DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve from Time Zero to the Last Time Point, Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity and 1 more. Started Jun 2023; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05914688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914688.